Integrating ctDNA Liquid Biopsy Tests into Routine Clinical Oncology

As demand grows for rapid, non-invasive, and comprehensive biomarker testing in oncology, liquid biopsies have become a powerful tool for tumor mutation profiling—supporting patient care and serving as an alternative when tissue samples are insufficient, lesions are inaccessible, or timely decisions are needed.

In this video, medical oncologist Vik Dabhi, MD, PhD, discusses strategies for adopting liquid biopsies in routine clinical care including optimal test selection and results interpretation. This presentation highlights features of Labcorp Plasma Complete, a 521-gene circulating tumor DNA (ctDNA) liquid biopsy test for advanced solid tumors that includes broad coverage of key genomic alterations, high sensitivity, and a fast turnaround time. Gain practical insights into how liquid biopsy is being integrated into routine clinical care to improve patient care.

Key takeaways include:

• An overview of the clinical value and use cases for liquid biopsy in solid tumors
• How Labcorp Plasma Complete enables broad genomic profiling aligned with guideline recommended biomarkers
• Practical insights into implementing liquid biopsy in oncology workflows
• A real-world case study demonstrating how liquid biopsy results have the potential to influence treatment decisions